Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
AssigneeNymox Corporation
InventorBenjamin Wolozin
Life of this patent
Estimating the term…
Abstract
Described are methods for treating, preventing, or reducing the risk of the onset of Alzheimer's disease by administering a therapeutically effective amount of an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (“HMG CoA reductase inhibitor”) to a patient who is at risk for a coronary or cerebrovascular event or at risk for Alzheimer's disease.
Claims22
A method for treating, preventing, or reducing the risk of Alzheimer's disease (AD) in a patient who has one or more risk factors for AD, comprising administering to a patient in need thereof a therapeutically effective amount of one or more inhibitors of the enzyme 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase, wherein:
- (a) the HMG CoA reductase inhibitor is not simvastatin
- (b) treatment results in a reduction or inhibition of onset of Alzheimer's disease,
- (c) the one or more risk factors are selected from the group consisting of hypercholesterolemia, coronary artery disease, family or previous history of coronary artery disease, hypertension, diabetes, cigarette smoking, cerebrovascular disease, cardiovascular disease, elevated serum cholesterol, heart disease, and male gender, and
- (d) the patient to be treated does not possess the APOE 4 gene.
A method for treating, preventing, or reducing the risk of Alzheimer's disease (AD) in a patient who has one or more risk factors for AD, comprising administering to a patient in need thereof a therapeutically effective amount of one or more inhibitors of the enzyme 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase, wherein:
- (a) the HMG CoA reductase inhibitor is not simvastatin,
- (b) treatment results in a reduction or inhibition of onset of Alzheimer's disease,
- (c) the one or more risk factors are selected from the group consisting of being 60 years of age or older, being exposed to environmental factors predisposing a patient to AD;
- having the α-2-macroglobulin genotype, having the presenilin I mutation for familial AD, having the presenilin II mutation for familial AD, having the amyloid precursor protein (APP) missense mutation for familial AD, having a family history of AD, having prior infection by the herpes simplex virus, and having prior infection by chlamydia pneumoniae, and
- (d) the patient to be treated does not possess the APOE 4 gene.
Dependencies are inferred from the claim text.